#VT109, a synthetic EB3 inhibitor, shows efficacy in murine #ARDS by restoring endothelial barriers, activating #FOXM1 repair, reducing #inflammation, and improving #LungFunction—emerging as a strong candidate for clinical testing.

#OpenAccess in #STTT: doi.org/10.1038/s413...